As previously reported, H.C. Wainwright downgraded IO Biotech (IOBT) to Neutral from Buy with no price target after the company gave an update from its pre-BLA meeting with the FDA and reported that the agency does not recommend that the company submit a BLA for Cylembio. Given the company’s cash position, the company would either need to raise additional capital, partner, or license out Cylembio to advance the new Phase 3 trial, says the analyst, who downgrades the shares based on the shift from a near-term regulatory review to planning a new large pivotal trial.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOBT:
- FDA Recommends Against IO Biotech’s Cylembio Application
- IO Biotech says FDA reccomends not submitting BLA based on IOB-013 trial data
- IO Biotech implements plan to conserve capital, 50% reduction in full-time staff
- IO Biotech Reports Q2 2025 Financial Results
- IO Biotech’s Cylembio Shows Promise Despite Missed Endpoint, Buy Rating Affirmed